GOSS Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Gossamer Bio Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerGOSS

Market Cap47.9M

Cash RunwayRunway 6-12 months

Next Catalyst2026-12

Public Research Snapshot

Gossamer Bio Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for Seralutinib in Pulmonary Arterial Hypertension (Phase 3).

Pipeline

Asset	Indication	Modality	Stage	Public Note
Seralutinib	Pulmonary Arterial Hypertension	n/a	Phase 3	Public pipeline row
The PROSERA Study	n/a	n/a	Phase 3	Public pipeline row
GB002	n/a	n/a	Phase 2	Public pipeline row
PROSERA Study	n/a	n/a	Phase 3	Public pipeline row
GB002 (seralutinib)	Pulmonary Arterial Hypertension	n/a	Phase 2	Public pipeline row
GB001	n/a	n/a	Phase 2	Public pipeline row

Catalyst Preview

Catalyst	Timing	Asset	Confidence
Clinical Trial Completion	2026-12	Seralutinib	Low
Clinical Trial Completion	2027-12	GB002 (seralutinib)	Low
Data Readout	December 2022	n/a	Low

Cash Runway Preview

Estimated cash runway: Runway 6-12 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT03956862	Phase 2	COMPLETED	97	2020-07-09
NCT04456998	Phase 2	COMPLETED	86	2022-10-17
NCT06274801	Phase 3	ACTIVE_NOT_RECRUITING	316	2026-12
NCT04816604	Phase 2	ACTIVE_NOT_RECRUITING	74	2027-12
NCT07181382	Phase 3	SUSPENDED	480	2028-12

Scientific Context

catalyst_type | Data Readout
catalyst_window | December 2022
clinical_stage | phase 3
conditions | Pulmonary Artery Hypertension
conditions | Safety Issues

Want the full GOSS research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.